Jazz Pharmaceuticals plc — Director's Dealing 2025

Jan 23, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-01-17

Reporting Person: Carr Patricia (SVP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-17	Ordinary Shares	A	1641	$0.0	Acquired	8237	Direct

Footnotes

F1: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified.